当前位置： SCI文献检索 > ANTIVIRAL THERAPY期刊下所有文献 > The first wave: HCV NS3 protease inhibitors telaprevir and boceprevir.

The first wave: HCV NS3 protease inhibitors telaprevir and boceprevir.

Abstract：

:Boceprevir and telaprevir are peptidomimetic serine protease inhibitors that have been recently approved for the treatment of HCV chronic infection. The addition of these drugs to the prior standard of care, pegylated interferon and ribavirin, improves sustained virological response rates for treatment-naive and treatment-experienced patients and shortens the duration of treatment for over half of treatment-naive patients. This review describes the clinical data supporting the approval and use of telaprevir and boceprevir, the algorithm for the use of these drugs, their adverse effects, as well as their important drug-drug interactions.

journal_name

Antivir Ther

journal_title

Antiviral therapy

authors

Marks KM,Jacobson IM

doi

10.3851/IMP2424

subject

Has Abstract

pub_date

2012-01-01 00:00:00

pages

1119-31

issue

6 Pt B

eissn

1359-6535

issn

2040-2058

journal_volume

17

pub_type

杂志文章,评审

相关文献

ANTIVIRAL THERAPY文献大全
  • Neither boosted elvitegravir nor darunavir with emtricitabine/tenofovir disoproxil fumarate increase insulin resistance in healthy volunteers: results from the STRIBILD-IR study.

    abstract：BACKGROUND:Insulin resistance (IR) was one of the first reported complications in HIV-positive patients who were receiving antiretroviral therapy (ART). However, the metabolic effects of newer fixed-dose ART combinations are unclear. METHODS:This Phase I prospective randomized open-label study evaluated the effects on...

    journal_title：Antiviral therapy

    pub_type： 杂志文章,随机对照试验

    doi：10.3851/IMP3049

    authors： Spinner CD,Kern KE,Zink A,Wolf E,Balogh A,Noe S,Von Werder A,Schwerdtfeger C,Schmid RM,Iakoubov R

    更新日期：2016-01-01 00:00:00

  • Short communication. Baseline factors associated with haematological toxicity that leads to a dosage reduction of pegylated interferon-alpha2a and ribavirin in HIV- and HCV-coinfected patients on HCV antiviral therapy.

    abstract：OBJECTIVE:To assess the baseline factors associated with haematological toxicity that lead to ribavirin or pegylated interferon (peginterferon) dosage reductions in hepatitis C and human immunodeficiency virus (HCV/HIV)-coinfected patients. DESIGN:Multicentre, prospective, observational study. SETTING:Eleven hospital...

    journal_title：Antiviral therapy

    pub_type： 临床试验,杂志文章,多中心研究

    doi：

    authors： Fuster D,Huertas JA,Gómez G,Solà R,González García J,Vilaró J,Pedrol E,Force L,Tor J,Sirera G,Videla S,Planas R,Clotet B,Tural C,PEG-TOX Research Group.

    更新日期：2005-01-01 00:00:00

  • Role of regulatory T-cells in immunization strategies involving a recombinant alphavirus vector system.

    abstract：BACKGROUND:Regulatory T-cells (Treg) hamper immune responses elicited by cancer vaccines. Therefore, depletion of Treg is being used to improve the outcome of vaccinations. METHODS:We studied whether an alphavirus vector-based immunotherapeutic vaccine changes the number and/or activity of Treg and if Treg depletion i...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：10.3851/IMP1751

    authors： Walczak M,Regts J,van Oosterhout AJ,Boon L,Wilschut J,Nijman HW,Daemen T

    更新日期：2011-01-01 00:00:00

  • Tenofovir-based antiretroviral therapy in 
HBV-HIV coinfection: results from the TREAT Asia HIV Observational Database.

    abstract：BACKGROUND:The World Health Organization recommends HBV-HIV-coinfected individuals start antiretroviral therapy containing tenofovir. Here we describe first-line tenofovir use and treatment outcomes in coinfected patients in Asia. METHODS:HBV surface antigen positive patients enrolled in the TREAT Asia HIV Observation...

    journal_title：Antiviral therapy

    pub_type： 杂志文章,多中心研究

    doi：10.3851/IMP2972

    authors： Boettiger DC,Kerr S,Ditangco R,Chaiwarith R,Li PC,Merati TP,Pham TT,Kiertiburanakul S,Kumarasamy N,Vonthanak S,Lee CK,Van Kinh N,Pujari S,Wong WW,Kamarulzaman A,Zhang F,Yunihastuti E,Choi JY,Oka S,Ng OT,Kantipong

    更新日期：2016-01-01 00:00:00

  • The potential role of HCV core antigen testing in diagnosing HCV infection.

    abstract：:The potential uses of serological tests that detect HCV core antigens in biological fluids are highlighted. The most common serological tests utilized to detect exposure to HCV rely on the detection of antibodies to HCV. However, these tests cannot distinguish between individuals who have resolved their infection and ...

    journal_title：Antiviral therapy

    pub_type： 杂志文章,评审

    doi：10.3851/IMP2463

    authors： Dawson GJ

    更新日期：2012-01-01 00:00:00

  • Survival after long-term ART exposure: findings from an Asian patient population retained in care beyond 5 years on ART.

    abstract：BACKGROUND:This study investigated survival in people living with HIV being followed-up from 5 and 10 years after antiretroviral therapy (ART) initiation in a multi-country Asian cohort. METHODS:We included patients in follow-up >5 years after ART initiation. Factors associated with mortality beyond 5 and 10 years on ...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：10.3851/IMP3358

    authors： Bijker R,Kiertiburanakul S,Kumarasamy N,Pujari S,Sun LP,Ng OT,Lee MP,Choi JY,Nguyen KV,Chan YJ,Merati TP,Cuong DD,Ross J,Jiamsakul A,IeDEA Asia-Pacific.

    更新日期：2020-01-01 00:00:00

  • Clinically relevant drug interactions with antiretroviral agents.

    abstract：:With the advent of the human immunodeficiency virus (HIV) protease inhibitors and the non-nucleoside reverse transcriptase inhibitors, the importance of drug-drug interactions with antiretroviral agents is becoming increasingly recognized. Every clinician involved in the care of HIV-infected persons should have a broa...

    journal_title：Antiviral therapy

    pub_type： 杂志文章,评审

    doi：

    authors： Burger DM,Hoetelmans RM,Koopmans PP,Meenhorst PL,Mulder JW,Hekster YA,Beijnen JH

    更新日期：1997-07-01 00:00:00

  • Modelling hepatitis C virus kinetics: the relationship between the infected cell loss rate and the final slope of viral decay.

    abstract：BACKGROUND:Patients infected with hepatitis C virus (HCV) who respond to treatment with interferon-alpha plus ribavirin exhibit biphasic or triphasic viral load decreases. While the rapid first phase is indicative of the effectiveness of therapy in blocking viral production (epsilon), the slope of the final phase (lamb...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：

    authors： Dahari H,Shudo E,Cotler SJ,Layden TJ,Perelson AS

    更新日期：2009-01-01 00:00:00

  • The prevalence, clinical features and response to antiviral therapy of patients with chronic hepatitis C who are seropositive for liver-kidney microsome type 1 antibodies.

    abstract：BACKGROUND:Antibodies to liver-kidney microsome type 1 (anti-LKM-1), which are a marker of autoimmune hepatitis, are found in a minority of patients with chronic hepatitis C virus (HCV) infection. Whether interferon/ribavirin therapy is safe and effective in these patients is unclear. AIM:To describe the prevalence, c...

    journal_title：Antiviral therapy

    pub_type： 临床试验,杂志文章

    doi：

    authors： Monti V,Aghemo A,Rumi MG,Donato MF,Del Ninno E,Colombo M

    更新日期：2005-01-01 00:00:00

  • Predictors of the virological response to a change in the antiretroviral treatment regimen in HIV-1-infected patients enrolled in a randomized trial comparing genotyping, phenotyping and standard of care (Narval trial, ANRS 088).

    abstract：OBJECTIVE:To identify predictors of the virological response to antiretroviral therapy in patients in whom initial therapy has failed. METHODS:The Narval trial was designed to compare phenotyping, genotyping and standard of care for the choice of antiretroviral therapy in patients in whom a protease inhibitor (PI)-con...

    journal_title：Antiviral therapy

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：

    authors： Vray M,Meynard JL,Dalban C,Morand-Joubert L,Clavel F,Brun-Vézinet F,Peytavin G,Costagliola D,Girard PM,Narval Trial Group.

    更新日期：2003-10-01 00:00:00

  • In combination, nucleoside reverse transcriptase inhibitors have significant effects on 3T3-L1 adipocyte lipid accumulation and survival.

    abstract：:The use of nucleoside reverse transcriptase inhibitors (NRTIs) for the treatment of HIV infection is clearly linked to the development of subcutaneous fat atrophy. Until recently, however, in vitro studies of adipocytes have shown no or only modest and inconsistent effects of these agents on adipocyte biology. This is...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：

    authors： Kosmiski LA,Miller HL,Klemm DJ

    更新日期：2006-01-01 00:00:00

  • Health economics in HIV disease.

    abstract：:All illnesses and, by association, all provision of health care in any setting have a cost, whether it is the direct cost to the consumer, to the provider (for example, a national health service) or the indirect cost to an employer or to society in lost production. Disease also has hidden or intangible costs of pain, ...

    journal_title：Antiviral therapy

    pub_type： 杂志文章,评审

    doi：

    authors： Youle M

    更新日期：1999-01-01 00:00:00

  • Infrequent transmission of HIV-1 drug-resistant variants.

    abstract：:Transmission of drug-resistant variants is influenced by several factors, including the prevalence of drug resistance in the population of HIV-1-infected patients, HIV-1 RNA levels and transmission by recently infected patients. In order to evaluate the impact of these factors on the transmission of drug-resistant var...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：

    authors： Yerly S,Jost S,Telenti A,Flepp M,Kaiser L,Chave JP,Vernazza P,Battegay M,Furrer H,Chanzy B,Burgisser P,Rickenbach M,Gebhardt M,Bernard MC,Perneger T,Hirschel B,Perrin L,Swiss HIV Cohort Study.

    更新日期：2004-06-01 00:00:00

  • Viral interaction and responses in chronic hepatitis C and B coinfected patients with interferon-alpha plus ribavirin combination therapy.

    abstract：BACKGROUND/AIMS:We conducted a case-control study to investigate the efficacy of interferon-alpha (IFN-alpha) and ribavirin combination therapy for patients with chronic hepatitis C and B virus (HCV/HBV) coinfection and to elucidate the interaction of these two viruses. METHODS:Forty-two chronic HCV/HBV-coinfected pat...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：

    authors： Chuang WL,Dai CY,Chang WY,Lee LP,Lin ZY,Chen SC,Hsieh MY,Wang LY,Yu ML

    更新日期：2005-01-01 00:00:00

  • Predicting antiretroviral drug resistance from the latest or the cumulative genotype.

    abstract：BACKGROUND:This study evaluates the added benefit when estimating antiretroviral drug resistance of combining all available resistance test results in a cumulative genotype relative to using the latest genotype alone. METHODS:The prevalence of resistance and genotypic sensitivity scores (GSS) predicted by the latest a...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：10.3851/IMP1753

    authors： Garcia F,Alvarez M,Fox Z,Garcia-Diaz A,Guillot V,Johnson M,Chueca N,Phillips A,Hernández-Quero J,Geretti AM

    更新日期：2011-01-01 00:00:00

  • The risk of developing peripheral neuropathy induced by nucleoside reverse transcriptase inhibitors decreases over time: evidence from the Delta trial.

    abstract：BACKGROUND:Peripheral neuropathy (PN) in HIV-infected individuals is thought be due to a toxic effect on mitochondria induced by some nucleoside reverse transcriptase inhibitors (NRTI). METHODS:A time-to-event analysis was performed using data from the Delta trial to study the incidence of PN in HIV-infected individua...

    journal_title：Antiviral therapy

    pub_type： 杂志文章,随机对照试验

    doi：

    authors： Arenas-Pinto A,Bhaskaran K,Dunn D,Weller IV

    更新日期：2008-01-01 00:00:00

  • Antiretroviral therapy in resource-limited settings: is there still a role for stavudine?

    abstract：:Phanuphak et al. compared three strategies for first-line antiretroviral therapy in 150 Thai patients: initiating therapy with zidovudine (AZT), tenofovir disoproxil fumarate (TDF), or a 24-week lead-in phase with stavudine (d4T) followed by a switch to AZT. Those taking d4T had higher haemoglobin levels and CD4(+) T-...

    journal_title：Antiviral therapy

    pub_type： 评论,杂志文章

    doi：10.3851/IMP2498

    authors： Gallant JE

    更新日期：2012-01-01 00:00:00

  • Identification of nonsense mutations in hepatitis B virus S gene in patients with hepatocellular carcinoma developed after lamivudine therapy.

    abstract：BACKGROUND:Lamivudine is widely used in patients with chronic hepatitis B virus (HBV) infection. In cirrhotic patients, long-term lamivudine therapy significantly reduced the risk of hepatocellular carcinoma (HCC). However, in a small but substantial portion of patients, HCC still developed despite lamivudine therapy. ...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：

    authors： Lai MW,Huang SF,Hsu CW,Chang MH,Liaw YF,Yeh CT

    更新日期：2009-01-01 00:00:00

  • Effect of nucleoside and nucleotide reverse transcriptase inhibitors of HIV on endogenous nucleotide pools.

    abstract：BACKGROUND:Alterations in endogenous nucleotide pools as a result of HIV therapy with nucleoside and nucleotide reverse transcriptase inhibitors (N[t]RTIs) is a proposed mechanism for therapy-related adverse events and drug interactions resulting in treatment failure. In vitro studies were performed in order to underst...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：

    authors： Vela JE,Miller MD,Rhodes GR,Ray AS

    更新日期：2008-01-01 00:00:00

  • Stability of liver fibrosis among HCV-infected injection drug users.

    abstract：BACKGROUND:There are few published data characterizing patterns of liver stiffness measurements (LSMs) among HCV-infected persons and their potential impact on clinical decisions (for example, deferring treatment and hepatocellular carcinoma surveillance). METHODS:A total of 591 HCV-infected injection drug users in a ...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：10.3851/IMP2085

    authors： Mehta SH,Kirk GD,Astemborski J,Sulkowski MS,Afdhal NH,Thomas DL

    更新日期：2012-01-01 00:00:00

  • Early low-molecular-weight heparin administration is associated with shorter time to SARS-CoV-2 swab negativity.

    abstract：BACKGROUND:Antiviral and immune-modulating properties of low-molecular-weight heparin (LMWH) against coronaviridae have been reported by in vitro studies, but no in vivo evidence is yet available. We sought to know whether the timing of prophylactic doses of LMWH during the course of COVID-19 may affect the time to SAR...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：10.3851/IMP3377

    authors： Trunfio M,Salvador E,Gaviraghi A,Audagnotto S,Marinaro L,Motta I,Casciaro R,Ghisetti V,Fava C,Bonora S,Di Perri G,Calcagno A,e-COVID Study Group.

    更新日期：2021-01-18 00:00:00

  • HIV drug resistance threshold survey using specimens from voluntary counselling and testing sites in Hanoi, Vietnam.

    abstract：BACKGROUND:In countries where antiretroviral therapy has been available or is being rapidly expanded, the World Health Organization (WHO) recommends surveillance for transmitted HIV drug resistance (HIVDR) by threshold surveillance methods using specimens from antenatal clinics or voluntary counselling and testing (VCT...

    journal_title：Antiviral therapy

    pub_type： 杂志文章,多中心研究

    doi：

    authors： Nguyen HT,Duc NB,Shrivastava R,Tran TH,Nguyen TA,Thang PH,McNicholl JM,Leelawiwat W,Chonwattana W,Sidibe K,Fujita M,Luu CM,Kakkar R,Bennett DE,Kaplan J,Cosimi L,Wolfe MI

    更新日期：2008-01-01 00:00:00

  • Combination antiviral therapy with lopinavir/ritonavir, arbidol and interferon-α1b for COVID-19.

    abstract：:Since the outbreak of coronavirus disease (COVID-19) that was discovered in 2019 in Wuhan, China, no standard therapy guideline has been set despite the severity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its high infectivity. The globally pandemic outbreak suggests that COVID-19 is highly inf...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：10.3851/IMP3362

    authors： Xie X,Jiang Y,Zeng Y,Liu H

    更新日期：2020-06-04 00:00:00

  • Assessing bias introduced in estimated glomerular filtration rate (eGFR) by the inhibition of creatinine tubular secretion from common antiretrovirals.

    abstract：BACKGROUND:Researchers must often rely on creatinine measurements to assess kidney function because direct glomerular filtration rates (GFR) and cystatin-c are rarely measured in routine clinical settings. However, HIV treatments often include dolutegravir, raltegravir, rilpivirine or cobicistat, which inhibit the prox...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：10.3851/IMP3373

    authors： Brunet L,Wyatt C,Hsu R,Mounzer K,Fusco J,Fusco G

    更新日期：2020-11-19 00:00:00

  • Long-term efficacy and safety of first-line therapy with once-daily saquinavir/ritonavir.

    abstract：BACKGROUND:The aim of this study was to assess the long-term efficacy and safety of first-line treatment with once-daily saquinavir/ritonavir plus two nucleoside reverse transcriptase inhibitors (NRTIs). METHODS:A total of 272 antiretroviral-naive patients with a CD4+ T-cell count of 200-350 cells/mm3 were treated wit...

    journal_title：Antiviral therapy

    pub_type： 杂志文章,多中心研究,随机对照试验

    doi：

    authors： Ananworanich J,Gayet-Ageron A,Ruxrungtham K,Chetchotisakd P,Prasithsirikul W,Kiertiburanakul S,Munsakul W,Raksakulkarn P,Tansuphasawadikul S,LeBraz M,Jupimai T,Ubolyam S,Schutz M,Hirschel B,Staccato Thailand Study Group.

    更新日期：2008-01-01 00:00:00

  • Exploiting information inherent in binding sites of virus-specific antibodies: design of an HCV vaccine candidate cross-reactive with multiple genotypes.

    abstract：BACKGROUND/AIMS:The role of antibody in hepatitis C virus (HCV) infection remains unclear although many reports attest to its role in viral clearance. Here we describe epitopes that are recognized by antibody present in the serum of infected patients and show that such epitopes can induce neutralizing antibodies. METH...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：

    authors： Grollo L,Torresi J,Drummer H,Zeng W,Williamson N,Jackson DC

    更新日期：2006-01-01 00:00:00

  • Hepatitis C virus kinetics.

    abstract：:The balance of virus production and clearance for untreated patients with chronic hepatitis C virus (HCV) results in a decline of viraemia when initiating active antiviral treatment. During the first phase of interferon-alpha therapy, after a delay of about 8-9 h, the kinetics of the viral load is characterized by a r...

    journal_title：Antiviral therapy

    pub_type： 杂志文章,评审

    doi：

    authors： Herrmann E,Neumann AU,Schmidt JM,Zeuzem S

    更新日期：2000-06-01 00:00:00

  • Serum hepatitis B surface antigen concentration correlates with HBV DNA level in patients with chronic hepatitis B.

    abstract：BACKGROUND:Serum HBV DNA level is crucial in the management of chronic hepatitis B (CHB); however, the assay is expensive and cannot be used widely. Therefore, we explored the possibility of hepatitis B surface antigen (HBsAg) quantification as a surrogate marker for HBV DNA level in CHB patients. METHODS:A total of 2...

    journal_title：Antiviral therapy

    pub_type： 杂志文章,随机对照试验

    doi：10.3851/IMP1696

    authors： Su TH,Hsu CS,Chen CL,Liu CH,Huang YW,Tseng TC,Liu CJ,Chen PJ,Lai MY,Chen DS,Kao JH

    更新日期：2010-01-01 00:00:00

  • A pilot case-control study of zidovudine compared with zidovudine plus didanosine in patients with advanced HIV-1 disease and no previous experience with antiretrovirals.

    abstract：:Although zidovudine (ZDV) is effective in HIV-1-infected patients, the duration of its efficacy may be short when treatment is started in advanced HIV disease. This pilot prospective case-control study was designed to evaluate the combination of ZDV plus didanosine [ddI] compared with ZDV monotherapy as an initial the...

    journal_title：Antiviral therapy

    pub_type： 临床试验,杂志文章

    doi：

    authors： Gatell JM,Leal M,Mallolas J,Vidal C,Pumarola T,Parra R,Padró S,Caruz A,Falgueras T,Rey C,Sánchez-Quijano A,Torres Y,Lissen E,Jiménez de Anta MT,Soriano E

    更新日期：1996-04-01 00:00:00

  • Pharmacokinetic study of once-daily versus twice-daily abacavir and lamivudine in HIV type-1-infected children aged 3-

    abstract：BACKGROUND:Once-daily dosing of abacavir and lamivudine has been approved for adults, but paediatric data are insufficient. We conducted a pharmacokinetic study of once-daily and twice-daily abacavir and lamivudine in children aged 3-<36 months. METHODS:Children with stable HIV type-1 (HIV-1) RNA levels after 12 weeks...

    journal_title：Antiviral therapy

    pub_type： 临床试验,杂志文章,多中心研究

    doi：10.3851/IMP1532

    authors： Paediatric European Network for Treatment of AIDS (PENTA).

    更新日期：2010-01-01 00:00:00